Altered amyloid protein processing in platelets of patients with Alzheimer disease

Roger N. Rosenberg, Fred Baskin, Jennifer A. Fosmire, Rick Risser, Perrie Adams, Doris Svetlik, Lawrence S. Honig, C. Munro Cullum, Myron F. Weiner

Research output: Contribution to journalArticle

97 Citations (Scopus)

Abstract

Background: β-Amyloid peptide, the core component of neuritic plaques in brain areas in patients with Alzheimer disease (AD), is 1 cleavage product of the β-amyloid precursor protein (APP) in neurons and platelets. Alternate cleavage products of intact 140- to 150-kd APPs in platelets include nonamyloidogenic 120- to 130-kd and 110-kd isoforms. The possible differential significance of these 2 isoforms, structurally similar to protease nexin II, is unknown. Objective: To determine whether the ratio of the 120-to 130-kd APP isoform to the 110-kd APP isoform as processed in platelets correlates with the presence of AD and/or the apolipoprotein E4 (ApoE4) allele, which is a major risk factor for AD. Setting: The Alzheimer Disease Center at The University of Texas Southwestern Medical Center at Dallas. Methods: The APP isoforms were quantitated with the use of 2 different Western blot detection methods in platelets from 15 patients with AD and 19 control subjects in whom genotyping of apolipoprotein E was performed. Results: The mean ratio of the 120- to 130-kd APP isoform to the 110-kd APP isoform in the patients with AD was significantly lower than that of the control subjects (5.98 vs 7.64; P=.03 [method 1] and 5.98 vs 7.92; P=.01 [method 21) after adjusting for age and the increased incidence of ApoE4 in patients with AD. The lower APP ratios were also associated with increased age and with the presence of an ApoE4 allele. Conclusions: The APP processing in platelets of patients with AD is different from that of control subjects. This difference, largely caused by factors other than the ApoE4 genotype, may reflect chronic platelet activation in patients with AD. The use of these data to estimate 'AD risk,' by using the APP isoform ratio, indicates an odds ratio of 1.75, suggesting possible utility as an adjunct in the diagnosis of AD. Moreover, these findings may relate to analogous alterations in APP processing that may occur in brain areas affected by AD.

Original languageEnglish (US)
Pages (from-to)139-144
Number of pages6
JournalArchives of Neurology
Volume54
Issue number2
StatePublished - 1997

Fingerprint

Amyloidogenic Proteins
Alzheimer Disease
Blood Platelets
Amyloid
Protein Isoforms
Amyloid beta-Protein Precursor
Apolipoprotein E4
Alzheimer's Disease
Protein
Alleles
Precursor
Platelet Activation
Amyloid Plaques
Brain
Apolipoproteins E
Western Blotting
Odds Ratio
Genotype

ASJC Scopus subject areas

  • Neuroscience(all)

Cite this

Rosenberg, R. N., Baskin, F., Fosmire, J. A., Risser, R., Adams, P., Svetlik, D., ... Weiner, M. F. (1997). Altered amyloid protein processing in platelets of patients with Alzheimer disease. Archives of Neurology, 54(2), 139-144.

Altered amyloid protein processing in platelets of patients with Alzheimer disease. / Rosenberg, Roger N.; Baskin, Fred; Fosmire, Jennifer A.; Risser, Rick; Adams, Perrie; Svetlik, Doris; Honig, Lawrence S.; Cullum, C. Munro; Weiner, Myron F.

In: Archives of Neurology, Vol. 54, No. 2, 1997, p. 139-144.

Research output: Contribution to journalArticle

Rosenberg, RN, Baskin, F, Fosmire, JA, Risser, R, Adams, P, Svetlik, D, Honig, LS, Cullum, CM & Weiner, MF 1997, 'Altered amyloid protein processing in platelets of patients with Alzheimer disease', Archives of Neurology, vol. 54, no. 2, pp. 139-144.
Rosenberg, Roger N. ; Baskin, Fred ; Fosmire, Jennifer A. ; Risser, Rick ; Adams, Perrie ; Svetlik, Doris ; Honig, Lawrence S. ; Cullum, C. Munro ; Weiner, Myron F. / Altered amyloid protein processing in platelets of patients with Alzheimer disease. In: Archives of Neurology. 1997 ; Vol. 54, No. 2. pp. 139-144.
@article{a853e63752614cecb8fb3b8589bff524,
title = "Altered amyloid protein processing in platelets of patients with Alzheimer disease",
abstract = "Background: β-Amyloid peptide, the core component of neuritic plaques in brain areas in patients with Alzheimer disease (AD), is 1 cleavage product of the β-amyloid precursor protein (APP) in neurons and platelets. Alternate cleavage products of intact 140- to 150-kd APPs in platelets include nonamyloidogenic 120- to 130-kd and 110-kd isoforms. The possible differential significance of these 2 isoforms, structurally similar to protease nexin II, is unknown. Objective: To determine whether the ratio of the 120-to 130-kd APP isoform to the 110-kd APP isoform as processed in platelets correlates with the presence of AD and/or the apolipoprotein E4 (ApoE4) allele, which is a major risk factor for AD. Setting: The Alzheimer Disease Center at The University of Texas Southwestern Medical Center at Dallas. Methods: The APP isoforms were quantitated with the use of 2 different Western blot detection methods in platelets from 15 patients with AD and 19 control subjects in whom genotyping of apolipoprotein E was performed. Results: The mean ratio of the 120- to 130-kd APP isoform to the 110-kd APP isoform in the patients with AD was significantly lower than that of the control subjects (5.98 vs 7.64; P=.03 [method 1] and 5.98 vs 7.92; P=.01 [method 21) after adjusting for age and the increased incidence of ApoE4 in patients with AD. The lower APP ratios were also associated with increased age and with the presence of an ApoE4 allele. Conclusions: The APP processing in platelets of patients with AD is different from that of control subjects. This difference, largely caused by factors other than the ApoE4 genotype, may reflect chronic platelet activation in patients with AD. The use of these data to estimate 'AD risk,' by using the APP isoform ratio, indicates an odds ratio of 1.75, suggesting possible utility as an adjunct in the diagnosis of AD. Moreover, these findings may relate to analogous alterations in APP processing that may occur in brain areas affected by AD.",
author = "Rosenberg, {Roger N.} and Fred Baskin and Fosmire, {Jennifer A.} and Rick Risser and Perrie Adams and Doris Svetlik and Honig, {Lawrence S.} and Cullum, {C. Munro} and Weiner, {Myron F.}",
year = "1997",
language = "English (US)",
volume = "54",
pages = "139--144",
journal = "Archives of Neurology",
issn = "0003-9942",
publisher = "American Medical Association",
number = "2",

}

TY - JOUR

T1 - Altered amyloid protein processing in platelets of patients with Alzheimer disease

AU - Rosenberg, Roger N.

AU - Baskin, Fred

AU - Fosmire, Jennifer A.

AU - Risser, Rick

AU - Adams, Perrie

AU - Svetlik, Doris

AU - Honig, Lawrence S.

AU - Cullum, C. Munro

AU - Weiner, Myron F.

PY - 1997

Y1 - 1997

N2 - Background: β-Amyloid peptide, the core component of neuritic plaques in brain areas in patients with Alzheimer disease (AD), is 1 cleavage product of the β-amyloid precursor protein (APP) in neurons and platelets. Alternate cleavage products of intact 140- to 150-kd APPs in platelets include nonamyloidogenic 120- to 130-kd and 110-kd isoforms. The possible differential significance of these 2 isoforms, structurally similar to protease nexin II, is unknown. Objective: To determine whether the ratio of the 120-to 130-kd APP isoform to the 110-kd APP isoform as processed in platelets correlates with the presence of AD and/or the apolipoprotein E4 (ApoE4) allele, which is a major risk factor for AD. Setting: The Alzheimer Disease Center at The University of Texas Southwestern Medical Center at Dallas. Methods: The APP isoforms were quantitated with the use of 2 different Western blot detection methods in platelets from 15 patients with AD and 19 control subjects in whom genotyping of apolipoprotein E was performed. Results: The mean ratio of the 120- to 130-kd APP isoform to the 110-kd APP isoform in the patients with AD was significantly lower than that of the control subjects (5.98 vs 7.64; P=.03 [method 1] and 5.98 vs 7.92; P=.01 [method 21) after adjusting for age and the increased incidence of ApoE4 in patients with AD. The lower APP ratios were also associated with increased age and with the presence of an ApoE4 allele. Conclusions: The APP processing in platelets of patients with AD is different from that of control subjects. This difference, largely caused by factors other than the ApoE4 genotype, may reflect chronic platelet activation in patients with AD. The use of these data to estimate 'AD risk,' by using the APP isoform ratio, indicates an odds ratio of 1.75, suggesting possible utility as an adjunct in the diagnosis of AD. Moreover, these findings may relate to analogous alterations in APP processing that may occur in brain areas affected by AD.

AB - Background: β-Amyloid peptide, the core component of neuritic plaques in brain areas in patients with Alzheimer disease (AD), is 1 cleavage product of the β-amyloid precursor protein (APP) in neurons and platelets. Alternate cleavage products of intact 140- to 150-kd APPs in platelets include nonamyloidogenic 120- to 130-kd and 110-kd isoforms. The possible differential significance of these 2 isoforms, structurally similar to protease nexin II, is unknown. Objective: To determine whether the ratio of the 120-to 130-kd APP isoform to the 110-kd APP isoform as processed in platelets correlates with the presence of AD and/or the apolipoprotein E4 (ApoE4) allele, which is a major risk factor for AD. Setting: The Alzheimer Disease Center at The University of Texas Southwestern Medical Center at Dallas. Methods: The APP isoforms were quantitated with the use of 2 different Western blot detection methods in platelets from 15 patients with AD and 19 control subjects in whom genotyping of apolipoprotein E was performed. Results: The mean ratio of the 120- to 130-kd APP isoform to the 110-kd APP isoform in the patients with AD was significantly lower than that of the control subjects (5.98 vs 7.64; P=.03 [method 1] and 5.98 vs 7.92; P=.01 [method 21) after adjusting for age and the increased incidence of ApoE4 in patients with AD. The lower APP ratios were also associated with increased age and with the presence of an ApoE4 allele. Conclusions: The APP processing in platelets of patients with AD is different from that of control subjects. This difference, largely caused by factors other than the ApoE4 genotype, may reflect chronic platelet activation in patients with AD. The use of these data to estimate 'AD risk,' by using the APP isoform ratio, indicates an odds ratio of 1.75, suggesting possible utility as an adjunct in the diagnosis of AD. Moreover, these findings may relate to analogous alterations in APP processing that may occur in brain areas affected by AD.

UR - http://www.scopus.com/inward/record.url?scp=0031047350&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0031047350&partnerID=8YFLogxK

M3 - Article

VL - 54

SP - 139

EP - 144

JO - Archives of Neurology

JF - Archives of Neurology

SN - 0003-9942

IS - 2

ER -